New drug hopes to strengthen muscles in rare genetic disorder
Disease control
Not yet recruiting
This study tests a medicine called surlorian in 28 adults with a rare genetic muscle disease (RYR1-related myopathy). The goal is to see if it improves muscle strength and is safe. Participants will be randomly assigned to receive surlorian or a placebo, and neither they nor the …
Phase: PHASE2 • Sponsor: RyCarma Therapeutics, Inc. • Aim: Disease control
Last updated May 06, 2026 16:13 UTC